SOLV Quote, Financials, Valuation and Earnings

Becton, Dickinson & Co. has a net margin of 60.4% compared to Solventum Corp.'s net margin of 8.37%. Solventum Corp.'s return on equity of 42.2% beat Becton, Dickinson & Co.'s return on equity of 6.6%.

Solventum Corp. has a consensus price target of $87.18, signalling upside risk potential of 1.21%. On the other hand Becton, Dickinson & Co. has an analysts' consensus of $206.67 which suggests that it could grow by 1.93%. Given that Becton, Dickinson & Co. has higher upside potential than Solventum Corp., analysts believe Becton, Dickinson & Co. is more attractive than Solventum Corp..

Solventum Corp. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Becton, Dickinson & Co. has a beta of 0.236, suggesting its less volatile than the S&P 500 by 76.383%.

Solventum Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Becton, Dickinson & Co. offers a yield of 2.06% to investors and pays a quarterly dividend of $1.05 per share. Solventum Corp. pays -- of its earnings as a dividend. Becton, Dickinson & Co. pays out 71.53% of its earnings as a dividend. Becton, Dickinson & Co.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Solventum Corp. quarterly revenues are $2.1B, which are smaller than Becton, Dickinson & Co. quarterly revenues of $5.9B. Solventum Corp.'s net income of $1.3B is higher than Becton, Dickinson & Co.'s net income of $493M. Notably, Solventum Corp.'s price-to-earnings ratio is 9.92x while Becton, Dickinson & Co.'s PE ratio is 34.78x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Solventum Corp. is 1.79x versus 2.67x for Becton, Dickinson & Co.. Usually stocks with elevated PS ratios are considered overvalued.

Boston Scientific Corp. has a net margin of 60.4% compared to Solventum Corp.'s net margin of 14.91%. Solventum Corp.'s return on equity of 42.2% beat Boston Scientific Corp.'s return on equity of 12.46%.

Solventum Corp. has a consensus price target of $87.18, signalling upside risk potential of 1.21%. On the other hand Boston Scientific Corp. has an analysts' consensus of $125.45 which suggests that it could grow by 28.48%. Given that Boston Scientific Corp. has higher upside potential than Solventum Corp., analysts believe Boston Scientific Corp. is more attractive than Solventum Corp..

Solventum Corp. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Boston Scientific Corp. has a beta of 0.670, suggesting its less volatile than the S&P 500 by 33.029%.

Solventum Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Boston Scientific Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Solventum Corp. pays -- of its earnings as a dividend. Boston Scientific Corp. pays out -- of its earnings as a dividend.

Solventum Corp. quarterly revenues are $2.1B, which are smaller than Boston Scientific Corp. quarterly revenues of $5.1B. Solventum Corp.'s net income of $1.3B is higher than Boston Scientific Corp.'s net income of $755M. Notably, Solventum Corp.'s price-to-earnings ratio is 9.92x while Boston Scientific Corp.'s PE ratio is 52.23x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Solventum Corp. is 1.79x versus 7.53x for Boston Scientific Corp.. Usually stocks with elevated PS ratios are considered overvalued.

Globus Medical, Inc. has a net margin of 60.4% compared to Solventum Corp.'s net margin of 15.47%. Solventum Corp.'s return on equity of 42.2% beat Globus Medical, Inc.'s return on equity of 10.08%.

Solventum Corp. has a consensus price target of $87.18, signalling upside risk potential of 1.21%. On the other hand Globus Medical, Inc. has an analysts' consensus of $106.40 which suggests that it could grow by 12.63%. Given that Globus Medical, Inc. has higher upside potential than Solventum Corp., analysts believe Globus Medical, Inc. is more attractive than Solventum Corp..

Solventum Corp. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Globus Medical, Inc. has a beta of 1.064, suggesting its more volatile than the S&P 500 by 6.426%.

Solventum Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Globus Medical, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Solventum Corp. pays -- of its earnings as a dividend. Globus Medical, Inc. pays out -- of its earnings as a dividend.

Solventum Corp. quarterly revenues are $2.1B, which are larger than Globus Medical, Inc. quarterly revenues of $769M. Solventum Corp.'s net income of $1.3B is higher than Globus Medical, Inc.'s net income of $119M. Notably, Solventum Corp.'s price-to-earnings ratio is 9.92x while Globus Medical, Inc.'s PE ratio is 30.53x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Solventum Corp. is 1.79x versus 4.70x for Globus Medical, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Dentsply Sirona, Inc. has a net margin of 60.4% compared to Solventum Corp.'s net margin of -47.35%. Solventum Corp.'s return on equity of 42.2% beat Dentsply Sirona, Inc.'s return on equity of -44.58%.

Solventum Corp. has a consensus price target of $87.18, signalling upside risk potential of 1.21%. On the other hand Dentsply Sirona, Inc. has an analysts' consensus of $12.83 which suggests that it could grow by 0.42%. Given that Solventum Corp. has higher upside potential than Dentsply Sirona, Inc., analysts believe Solventum Corp. is more attractive than Dentsply Sirona, Inc..

Solventum Corp. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Dentsply Sirona, Inc. has a beta of 0.997, suggesting its less volatile than the S&P 500 by 0.3%.

Solventum Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Dentsply Sirona, Inc. offers a yield of 5.01% to investors and pays a quarterly dividend of $0.16 per share. Solventum Corp. pays -- of its earnings as a dividend. Dentsply Sirona, Inc. pays out 13.85% of its earnings as a dividend. Dentsply Sirona, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Solventum Corp. quarterly revenues are $2.1B, which are larger than Dentsply Sirona, Inc. quarterly revenues of $904M. Solventum Corp.'s net income of $1.3B is higher than Dentsply Sirona, Inc.'s net income of -$428M. Notably, Solventum Corp.'s price-to-earnings ratio is 9.92x while Dentsply Sirona, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Solventum Corp. is 1.79x versus 0.70x for Dentsply Sirona, Inc.. Usually stocks with elevated PS ratios are considered overvalued.